Page 79 - TequioVol1No2

Cáncer hepático /Ramírez et al./69-77 77

Liu, H. (2015). Fruit and vegetable consumption Sun, H. y Song, T. (2015). Hepatocellular carcinoma:
and risk of bladder cancer: an updated meta- advances in diagnostic imaging. Drug Discov Ther,
analysis of observational studies. Eur J Cancer 9, 310-318.
Prev, 24, 508-516.
Tomimaru, Y., Eguchi, H., Nagano, H., Wada,
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., H., Kobayashi, S., Marubashi, S., et al. (2012).
Gane, E., Blanc, J. F., De Oliveira, A. C., Santoro, Circulating microRNA-21 as a novel biomarker for
A., Raoul, J. L., Forner, A., Schwartz, M., Porta, C., hepatocellular carcinoma. Journal of Hepatology,
Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., 56, 167-175.
Seitz, J. F., Borbath, I., Häussinger, D., Giannaris,
T., Shan, M., Moscovici, M., Voliotis, D. y Bruix, J. Wang, Z., Ding, Q., Li, Y., Liu, Q., Wu, W., Wu,
(2008). Sorafenib in advanced hepatocellular L. y Yu, H. (2016). Reanalysis of microRNA
carcinoma. N Engl J Med., 359, 378e90. expression profiles identifies novel biomarkers for
hepatocellular carcinoma prognosis. Tumour Biol.,
Maitri, Y., Ferrajoli, A., Sood, A. K., López-Berestein, G. 37(11), 1-9.
y Calin, G. (2016). MicroRNA Therapeutics in Cancer-
an Emerging Concept. EBioMedicine, 12, 34-42. Williams, R. (2014). Addressing liver disease in the
UK: a blueprint for attaining excellence in health
Plancarte, R., Guillén, M. R., Guajardo, J. y care and reducing premature mortality from
Mayer, F. (2004). Ascites in cancer patients. lifestyle issues of excess consumption of alcohol,
Physiopathology and therapeutic options. Rev Soc obesity and viral hepatitis. Lancet, 384(9958),
Esp Dolor, 11, 156-162. 1953-1997.

Secretaría de Salud. 2014. Mortalidad. Dirección Yao, W. F., Liu, J. W., Sheng, G. L. y Huang, D. S.
general de información en salud. México, D.F. (2011). Blockade of IGF-IR exerts anticancer
effects in hepatocellular carcinoma. Mol Med Rep.,
Shyh-Horng, C. y King-Teh, L. (2016). Proteomic 4(4), 719-722.
analysis and translational perspective of
hepatocellular carcinoma: Identification of diagnostic Yang, Y., Li, M., Chang, S., Wang, L., Song, T., Gao,
protein biomarkers by an onco-proteogenomics L., Hu, L., Li, Z., Liu, L., Yao, J. y Huang, C. (2014).
approach. Elsevier, 32(11), 535-544. MicroRNA-195 acts as a tumor suppressor by
directly targeting Wnt3a in HepG2 hepatocellular
Singal, A., Volk, M. L., Waljee, A., Salgia, R., Higgins, P., carcinoma cells. Mol Med Rep., 10(5), 2643-2648.
Rogers, M. A. y Marrero, J. A. (2009). Meta-analysis:
surveillance with ultrasound for earlystage Yang, Y., Zhao, Z., Hou, N., Li, Y., Wang, X., Wu,
hepatocellular carcinoma in patients with cirrhosis. F., Sun, R., Han, J., Sun, H., Song, T., Huang, C. y
Aliment Pharmacol Ther., 30, 37-47. Shao, Y. (2017). MicroRNA 214 targets Wnt3a to
suppress liver cáncer cell proliferation. Mol Med
SMeO. (2012). Guía mexicana de tratamiento del Rep., 16(5), 6920-6927.
hepatocarcinoma avanzado. Gaceta Mexicana de
Oncología, 11, Supl. 2.
Zaytseva, Y. Y., Valentino, J. D., Gulhati, P. y Evers,
Song, P. P., Xia, J. F., Inagaki, Y., Hasegawa, K., B. M. (2012). MTOR inhibitors in cancer therapy.
Sakamoto, Y., Kokudo, N. y Tang, W. (2016). Cancer Lett, 319, 1-7.
Controversies regarding and perspectives on
clinical utility of biomarkers in hepatocellular
carcinoma. World J Gastroenterol, 22, 262-274.

Sun, G., Zhang, C., Feng, M., Liu, W., Xie, H., Qin, Q.,
Zhao, E. y Wan, L. (2017). Methylation analysis
of p16, SLIT2, SCARA5, and Runx3 genes in
hepatocellular carcinoma. Medicine, 96(41), e8279.

Tequio, vol. 1, no. 2, enero-abril, 2018